$41.08
+5.61 (+15.82%)
U News26 articles
Unity Stock Jumps 14% on Q2 Beat, Strategic Revenue Growth
Unity Software (U) shares jumped 14% after Q2 revenue and EBITDA beat estimates, driven by strategic revenue growth. The company raised its outlook for Q3.
Roblox shares near low as safety costs outpace user spending
Roblox shares hover near their 52-week low as increased safety spending outpaces user monetization, with Q3 bookings guidance missing estimates.
Roblox stock crashes 27% as bookings gap raises growth doubts
Roblox shares tumbled 27% on Friday after the company's Q3 bookings outlook disappointed, highlighting a growing gap between bookings and recognized revenue.
Roblox Shares Tumble 27% on North America Monetization Woes
Roblox shares fell 27% after weak Q3 bookings guidance, with U.S./Canada monetization lagging. The stock closed at $35.60, its worst day on record.
Roblox Stock Tumbles 21% as User Spending Slows
Roblox shares plunged 21% in premarket trading after the company reported a decline in spending per user and issued a weak Q3 bookings outlook.
Unity's AI Ad Engine Drives Revenue Growth, But Impairment Charge Weighs on Earnings
Unity Software posted a 17% revenue increase in Q1 2026, fueled by its AI-powered ad engine, but a $279 million impairment charge widened its net loss to $347 million.
Wall Street Extends Slide as Oil Spike, Tech Weakness Fuel Selloff
U.S. stocks extended their weekly decline, with the S&P 500 and Nasdaq Composite closing at their lowest levels in six months. A sharp rise in crude oil prices and persistent weakness in major technology shares pressured the broader market.
Unity Stock Soars on Upbeat Q1 Forecast and Strategic Divestment Plan
Unity Software's stock jumped 11% to $19.01 following an improved first-quarter outlook and a strategic decision to divest slower-growth advertising and publishing units.
Stocks Slide, Oil Soars as Iran Deadline Extension Fails to Calm Markets
Wall Street declined sharply on Friday, with the S&P 500 and Nasdaq Composite both falling over 0.9%, while Brent crude oil jumped above $110 a barrel after the White House extended a key deadline in the Iran conflict, raising concerns over prolonged inflation and interest rates.
Unity Software Plunges on Weak Q1 Forecast, AI Concerns
Unity Software shares dropped nearly 10% following a weak first-quarter revenue forecast and analyst warnings about competitive threats from artificial intelligence.
Unity Stock Stabilizes After Sharp Guidance Cut, AI Concerns Loom
Unity shares held near $21.41 in premarket trading following a 26% plunge after the company issued weaker-than-expected Q1 revenue guidance. Investors are monitoring demand for its Create tools and advertising segment.
Transocean Shares Up 2.2% on Merger Arbitrage Opportunity as Valaris Deal Spread Widens
Transocean shares advanced 2.2% amid a widening merger spread with Valaris to 2.4%, as regulatory milestones and robust Q2 guidance bolster arbitrage expectations.
Hims & Hers Peptide Opportunity Tempered by FDA Timeline
Hims & Hers (HIMS) rose 3.4% after FDA advisers supported four unapproved peptides for compounding, but the final rule may take up to a year. Analysts estimate $440M in peptide sales by 2027.
Telix Pharma Slides 8.4% in Five Days, Japan Opportunity Excluded from 2026 Guidance
Telix Pharmaceuticals (ASX:TLX) shares fell 8.4% in five sessions, trailing the ASX 200 by 8.3 points. Enrollment in Japan Phase 3 reached 105 patients, but Japan remains outside 2026 revenue guidance.
ImmunityBio Faces Key Warrant Expiry Test on July 24 After Friday Rebound
ImmunityBio (NASDAQ:IBRX) faces a crucial warrant expiry on July 24, with up to 6.4 million shares potentially exercised, testing trading liquidity after a Friday rebound.
CoreWeave Rebounds 7.75% After Meta-Fueled Selloff, Analysts See Buying Opportunity
CoreWeave shares surged 7.75% to $90.00, rebounding from last week's drop linked to Meta's potential competition. Analysts see a buying opportunity, with Wolfe Research maintaining a $150 target.
T1 Energy Faces July 9 Warrant Expiry Amid $283M Cash Opportunity
T1 Energy Inc. (NYSE:TE) faces a critical July 9 warrant deadline, with $282.9 million in potential proceeds if all 24.6 million warrants are exercised at $11.50 per share.
ImmunityBio Volume Surges on Russell Index Changes; Monday Trading Key
ImmunityBio surged 11.8% on Friday with volume tripling its average, driven by Russell index reconstitution. Monday's trading will reveal if the spike holds.
ImmunityBio Jumps on Russell Index Rebalancing and High Valuation
ImmunityBio surged 9.2% to $8.51 as its market cap exceeded the Russell 1000 cutoff, drawing buyers ahead of index reconstitution.
Virgin Galactic Soars 36% on VSS Unity Glide Flights
Virgin Galactic shares jumped 36% on record volume after resuming VSS Unity glide flights, with new spaceship tests targeted for Q3 and a 2027 research mission.
ImmunityBio's Anktiva Expansion Faces FDA Scrutiny with 2027 Decision Date
ImmunityBio's supplemental BLA for Anktiva in papillary-only bladder cancer has been accepted by the FDA, with a decision expected by Jan. 6, 2027. The company's stock traded at $7.76, down 2.8%.
ImmunityBio Secures Patents and BCG Supply Deal for Bladder Cancer Therapy
ImmunityBio announced five U.S. patents protecting its Anktiva-plus-BCG bladder cancer therapy through 2035, and an exclusive supply deal for the Tokyo-172 BCG strain.
ImmunityBio Secures Exclusive US Rights to Japan BCG Strain for Bladder Cancer
ImmunityBio announced exclusive U.S. rights to Japan BCG Laboratory's Tokyo-172 BCG strain for bladder cancer therapy, with FDA discussions planned. Shares closed at $7.97 Friday, down 2.2%.
ImmunityBio Surges on NK-Cell Manufacturing Milestone, Anktiva Expansion Progress
ImmunityBio shares jumped 10.5% Friday following news of a completed scalable manufacturing process for its NK-cell therapy platform and regulatory progress for its drug Anktiva. The company also reported surging 2025 revenue.
ImmunityBio Shares Dip Ahead of Key Business Update Call
ImmunityBio shares edged lower in premarket activity Tuesday, giving back some of the prior session's gains ahead of a scheduled business update and full-year results call later in the day.
ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.